Group 1 - On September 10, Yinos achieved a stock price increase of 3.57% with a trading volume of 79.4568 million yuan, and the net financing purchase amounted to 3.0738 million yuan [1] - As of September 10, the total balance of margin trading for Yinos was 88.5422 million yuan, which represents 2.51% of its circulating market value [1] - Yinos primarily operates in the field of biopharmaceutical non-clinical research services, with 96.31% of its revenue coming from non-clinical services [1] Group 2 - As of June 30, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - For the first half of 2025, Yinos reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - After its A-share listing, Yinos has distributed a total of 45.1135 million yuan in dividends [2]
益诺思9月10日获融资买入777.79万元，融资余额8854.22万元